AbbVie Inc. (ABBV) Stock AnalysisABBVAbbVie Inc.

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Restasis. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its pipeline also includes zumilokibart and APG273. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

AbbVie Inc is a good buy right now due to its strong financial performance, including a gross margin of 74.74% in Q2 2026 and a forward P/E ratio of 16.39, which indicates reasonable valuation compared to its earnings potential. Additionally, the stock has shown a year-to-date change of +24.47%, reflecting positive momentum. However, the main risk is its high debt level, with total debt at $70.8 billion, which could impact financial stability if not managed properly.

20 analysts cover ABBV: 10 rate it Buy, 10 Hold and 0 Sell. The average price target is 252.00.